# A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

> **NCT03217812** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 220 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Velcade
- **DRUG:** Melphalan
- **DRUG:** Prednisone
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT03217812
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-23
- **Primary completion:** 2020-07-02
- **Final completion:** 2024-03-08
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03217812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03217812, "A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03217812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*